Keywords: Johnson & Johnson,Janssen, Abiraterone, Prostate cancer, ESMO, Datamonitor

Janssen/J&J’s abiraterone significantly improved overall survival for advanced prostate cancer patients; but how to use it?

Article | 12 October 2010

Johnson & Johnson (NYSE: JNJ) affiliate Janssen Pharmaceutica says that results from a pre-specified interim analysis of a randomized, placebo-controlled ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Janssen Pharmaceutica

Johnson & Johnson

Go to company listing

Related Drugs

abiraterone

Go to drug listing